What You Should Know:
- The American Cancer Society (ACS) and Yosemite, an oncology-focused venture capital firm, announced the selection of research grants through their Yosemite-ACS Award totaling more than $6 million.
- These inaugural grants will go to scientists from institutions across the country and are poised to make an impact in immuno-oncology as well as the use of Artificial Intelligence (AI) in cancer prevention, detection, treatment, and healthcare delivery.
American Cancer Society and Yosemite: Advancing Cancer Research Through Strategic Partnership
Collaborating to End Cancer for Everyone
The American Cancer Society (ACS), a leader in the fight against cancer for over 110 years, remains committed to improving the lives of cancer patients and their families. As the only organization addressing cancer through advocacy, research, and patient support, ACS strives to ensure that everyone has access to cancer prevention, detection, treatment, and survival.
Yosemite, a firm dedicated to making cancer non-lethal within our lifetime, partners with leading researchers and entrepreneurs to fund advancements in oncology. By deploying capital from early-stage non-profit grantees to late-stage companies, Yosemite aims to accelerate the development of new therapies and optimize patient experiences across the oncology ecosystem.
Yosemite-ACS Award: Fostering Groundbreaking Research
In collaboration with ACS, Yosemite developed the Yosemite-ACS Award to support innovative cancer research across the United States. This award combines Yosemite’s science-first approach and no-strings-attached grantmaking with ACS’s commitment to ending cancer. The partnership supports cutting-edge research that aligns with the shared goal of advancing cancer treatment and patient care.
According to Dr. William Dahut, ACS’s Chief Scientific Officer, “The American Cancer Society is proud to collaborate with Yosemite to support innovative research employing molecular research, immunotherapy, AI, and computational machine learning to advance cancer therapies.”
Driving Impactful Research in 2024 and Beyond
The 2024 Yosemite-ACS Award supports projects led by both early-career and internationally recognized researchers. Key areas of focus include:
– Accelerating immunotherapy discovery and effectiveness
– Understanding molecular mechanisms of immunity
– Leveraging AI to improve patient care and healthcare access
In 2025, Yosemite and ACS will continue to expand their grant funding, aiming to provide more support to the scientific community and foster impactful cancer research.
